drugset / Trial / NCT01994239

Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy

NCT01994239

Phase 2 Active not recruiting 120 enrolled UNICANCER Ferring Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to select the best therapeutic strategy in studying the effectiveness of the association of a short duration hormonal therapy and radiotherapy compared with radiotherapy alone, in patients with a detectable PSA after radical prostatectomy.

Timeline

Start
2012-12
Primary completion
2022-03
Completion
2025-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Degarelix Other / unclassified 80 mg